news
Dementia finally gets a business model, driven by new drugs.
Opinion piece from the Alzheimer's Association International Conference suggests dementia care and research now have a viable business model. This shift is reportedly fueled by new drug development like lecanemab and donanemab for Alzheimer's, creating incentives for investment and patient services. The writer posits this changes how we'll approach cognitive decline going forward.
Opinion piece from the Alzheimer's Association International Conference suggests dementia care and research now have a viable business model. This shift is reportedly fueled by new drug development like lecanemab and donanemab for Alzheimer's, creating incentives for investment and patient services. The writer posits this changes how we'll approach cognitive decline going forward.
The architecture take
Call it what it is: the 'sick care' model finally caught up to dementia. For decades, pharma basically shrugged at Alzheimer's and cognitive decline because the ROI wasn't there. Now, with new amyloid-targeting drugs (hello, lecanemab and donanemab) actually getting approved, suddenly billions are flowing into R&D and specialized centers. The money's coming from Medicare covering these pricey infusions, insurers following suit, and clinics popping up to deliver them. It's smart business, maybe not so much 'wellness.' What this really means is that proactive, nervous-system-first brain health largely remains an 'uninsured' space, while the big money chases late-stage disease management. You'll see more specialized dementia clinics, but don't expect your HMO to cover an eight-week vagus nerve toning program anytime soon, even if it might move the needle on early cognitive health.